Weight-Loss Drugs Show Signs of Slowing Biological Aging, Drugmakers Say

For millions of people, the appeal of drugs like Ozempic and Zepbound has always been simple: they help you lose weight. But new data suggests something more complicated, and more hopeful, might be happening inside the body. According to the companies that make these blockbuster drugs, patients taking them may actually be aging more slowly at a molecular level.

Eli Lilly and Novo Nordisk, the two pharmaceutical giants behind the world's most popular weight-loss drugs, presented findings over the weekend showing that patients on their GLP-1 medications had lower "biological age" readings than those on a placebo. The data came from an emerging class of tools called aging clocks, which estimate how old your cells and organs really are, as opposed to how many birthdays you've had.

Think of biological age as a car's odometer versus its actual wear and tear. Two vehicles might be the same model year, but one that's been driven gently and maintained well will have less engine wear than one pushed hard on rough roads. Aging clocks try to measure that wear and tear in the human body by tracking chemical changes to DNA, or in newer versions, by measuring levels of key proteins in the blood.

The companies shared their results at Aging Research & Drug Discovery, a conference focused on the science of extending healthy life. Novo reported an average reduction in biological age of roughly two to three years among patients, according to Nikolaj Roed, a global project leader at the company. He said Novo has observed "improved biological age in our patients across trials and across different tissues."

For some scientists in the field, that's a significant number. "Two years is a pretty strong effect, in my book," said Steve Horvath, a UCLA professor widely credited with inventing the first aging clocks. Horvath said the emerging evidence could suggest these drugs function as geroprotectors, a term for medications that slow or even reverse biological aging rather than simply treating individual diseases.

What the Data Actually Shows

Novo's study drew blood from more than 10,000 participants, split evenly between those taking the drug and those on a placebo. Researchers measured those samples using what are called proteomic clocks, which estimate age and mortality risk based on protein levels in the blood. The company found that intervention with semaglutide, the active ingredient in Ozempic and Wegovy, measurably shifted the clocks, in some cases by as much as four years when looking at proteins tied to heart health.

Eli Lilly ran a parallel, smaller study on its own drug, tirzepatide, sold as Mounjaro and Zepbound, using epigenetic clocks that track chemical modifications to DNA rather than protein levels. The results pointed in the same direction. "All the clocks are telling a consistent story that we're seeing a reduction in age," said Kevin Duffin, Lilly's vice president for aging research. He was careful to temper expectations, though. "It's not like we're going to reverse age by 30 years or something, but it's a significant reduction."

It's worth remembering what these drugs were originally built to do. GLP-1 medications work by activating a receptor that signals fullness to the brain, curbing appetite and driving weight loss. But real-world data has shown effects well beyond the waistline. Studies have linked the drugs to improved kidney function, lower blood pressure, and a meaningfully reduced risk of death from any cause. That broader pattern is part of why scientists are now asking whether something more fundamental than weight loss is at work.

"If the question is, can semaglutide reach several diseases relevant to health span and aging, we know we can say the answer is yes," said Alejandro Aguayo-Orozco, a senior scientific director at Novo, during the conference. The next question, he said, was whether those health benefits show up in the molecular clocks too. "And the answer is yes."

These findings also matter for a separate reason: they offer a kind of validation for aging clocks themselves. Until now, it's been genuinely unclear whether these tools measure anything biologically meaningful, or whether they're just an interesting statistical exercise. Seeing the clocks move in the expected direction, alongside a drug with well-documented health benefits, gives researchers more confidence the measurements are tracking something real. "The clock people have been pushing for a decade to get this kind of study done," said Yuge Ji, a biologist who now runs the startup Reflector Bio. "It's huge for them."

Not everyone is ready to declare victory, though. Vadim Gladyshev, a Harvard biologist who worked with Novo on its molecular measurements, put it plainly: "In an unhealthy population, I do think it's an anti-aging drug. But in a healthy population, no one knows." That distinction matters enormously. Most of the people studied so far were overweight, obese, or diabetic, meaning the drugs may simply be undoing damage caused by those conditions rather than slowing aging in a universal sense.

Horvath raised a similar caution, noting the drugs carry real side effects, including muscle loss, that could outweigh any benefit in people who aren't already sick. "Clearly, the drugs have many benefits in obese people, but I did not yet see sufficient evidence that they will benefit skinny people," he said. "I guess we will have to wait."

Why It Matters

The stakes here go well beyond one drug class. Alex Zhavoronkov, founder of Insilico Medicine and organizer of the Boston conference, has argued that extending the average human lifespan by even a single year, applied across the global population, would be equivalent to tens of millions of additional lifetimes. He disclosed during the event that he personally takes both tirzepatide and semaglutide in small doses, despite not being overweight, a choice that drew pointed questions from the audience about whether healthy people should consider doing the same. Aguayo-Orozco declined to weigh in, saying simply, "I am not a physician. I cannot answer that question."

That uncertainty is exactly what a new federally funded study aims to resolve. In January, the U.S. agency ARPA-H committed $38 million to a Texas-based trial testing whether semaglutide produces anti-aging effects in healthy adults over 60, tracking changes in cognition, mobility, and sensory function. The project also hopes to help define a regulatory pathway for future longevity drugs. For now, these billion-dollar weight-loss drugs remain exactly that: treatments for obesity and diabetes with striking secondary benefits. Whether they become the first mass-market anti-aging medicine is a question that will take real clinical evidence, not conference buzz, to answer.